Larimar Therapeutics Net Worth
Larimar Therapeutics Net Worth Breakdown | LRMR |
Larimar Therapeutics Net Worth Analysis
Larimar Therapeutics' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Larimar Therapeutics' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Larimar Therapeutics' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Larimar Therapeutics' net worth analysis. One common approach is to calculate Larimar Therapeutics' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Larimar Therapeutics' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Larimar Therapeutics' net worth. This approach calculates the present value of Larimar Therapeutics' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Larimar Therapeutics' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Larimar Therapeutics' net worth. This involves comparing Larimar Therapeutics' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Larimar Therapeutics' net worth relative to its peers.
Enterprise Value |
|
To determine if Larimar Therapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Larimar Therapeutics' net worth research are outlined below:
| Larimar Therapeutics generated a negative expected return over the last 90 days | |
| Larimar Therapeutics has high historical volatility and very poor performance | |
| Net Loss for the year was (36.95 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Larimar Therapeutics currently holds about 54.92 M in cash with (33.46 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.1, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Larimar Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Over 98.0% of the company shares are owned by institutional investors | |
| Latest headline from news.google.com: Larimar Therapeutics files for 300M mixed shelf offering - MSN |
Larimar Therapeutics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Larimar Therapeutics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Larimar Therapeutics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 12th of March 2024 Upcoming Quarterly Report | View | |
| 20th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 12th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Larimar Therapeutics Target Price Consensus
Larimar target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Larimar Therapeutics' target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 11 | Strong Buy |
Most Larimar analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Larimar stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Larimar Therapeutics, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationLarimar Therapeutics Target Price Projection
Larimar Therapeutics' current and average target prices are 2.54 and 20.41, respectively. The current price of Larimar Therapeutics is the price at which Larimar Therapeutics is currently trading. On the other hand, Larimar Therapeutics' target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Current Price
Larimar Therapeutics Market Quote on 21st of March 2025
Target Price
Analyst Consensus On Larimar Therapeutics Target Price
Know Larimar Therapeutics' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Larimar Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Larimar Therapeutics backward and forwards among themselves. Larimar Therapeutics' institutional investor refers to the entity that pools money to purchase Larimar Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Geode Capital Management, Llc | 2024-12-31 | 886.4 K | State Street Corp | 2024-12-31 | 842.9 K | Mangrove Partners | 2024-12-31 | 770.2 K | Fred Alger Management, Llc | 2024-12-31 | 737.6 K | Woodline Partners Lp | 2024-12-31 | 622.7 K | Renaissance Technologies Corp | 2024-12-31 | 513.5 K | Altium Capital Management, Lp | 2024-12-31 | 505 K | Sphera Funds Management Ltd. | 2024-12-31 | 455.6 K | Northern Trust Corp | 2024-12-31 | 376.5 K | Deerfield Management Co | 2024-12-31 | 21.2 M | Hhg Plc | 2024-12-31 | 6.4 M |
Follow Larimar Therapeutics' market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 160.15 M.Market Cap |
|
Project Larimar Therapeutics' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.44) | (0.47) | |
| Return On Capital Employed | (0.43) | (0.41) | |
| Return On Assets | (0.44) | (0.47) | |
| Return On Equity | (0.41) | (0.39) |
When accessing Larimar Therapeutics' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Larimar Therapeutics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Larimar Therapeutics' profitability and make more informed investment decisions.
Evaluate Larimar Therapeutics' management efficiency
Larimar Therapeutics has return on total asset (ROA) of (0.2855) % which means that it has lost $0.2855 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.445) %, meaning that it created substantial loss on money invested by shareholders. Larimar Therapeutics' management efficiency ratios could be used to measure how well Larimar Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of 03/21/2025, Return On Tangible Assets is likely to drop to -0.47. In addition to that, Return On Capital Employed is likely to grow to -0.41. At this time, Larimar Therapeutics' Non Current Assets Total are relatively stable compared to the past year. As of 03/21/2025, Non Currrent Assets Other is likely to grow to about 795.7 K, while Other Current Assets are likely to drop slightly above 2.4 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 2.14 | 2.03 | |
| Tangible Book Value Per Share | 2.14 | 2.03 | |
| Enterprise Value Over EBITDA | (3.88) | (4.07) | |
| Price Book Value Ratio | 2.81 | 2.95 | |
| Enterprise Value Multiple | (3.88) | (4.07) | |
| Price Fair Value | 2.81 | 2.95 | |
| Enterprise Value | 205.3 M | 217.4 M |
Larimar Therapeutics has shown resilience through effective management strategies. Our analysis examines how these strategies influence financial outcomes and investor returns which helps in understanding the stock's long-term potential.
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Larimar Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Larimar Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Larimar Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Larimar Therapeutics Corporate Filings
| 4th of February 2025 Other Reports | ViewVerify | |
8K | 27th of January 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 24th of January 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
| 8th of January 2025 Other Reports | ViewVerify |
Larimar Therapeutics Earnings per Share Projection vs Actual
Larimar Therapeutics Corporate Management
| Gopi MBA | Chief Officer | Profile | |
| DO Sr | Chief Officer | Profile | |
| Francis Conway | VP Controller | Profile | |
| Sr DO | Chief Officer | Profile | |
| John Berman | Vice Administration | Profile |
Additional Tools for Larimar Stock Analysis
When running Larimar Therapeutics' price analysis, check to measure Larimar Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Larimar Therapeutics is operating at the current time. Most of Larimar Therapeutics' value examination focuses on studying past and present price action to predict the probability of Larimar Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Larimar Therapeutics' price. Additionally, you may evaluate how the addition of Larimar Therapeutics to your portfolios can decrease your overall portfolio volatility.